PL3 Stock Chart & Stats
€2.48
€0.00(0.00%)
At close: 4:00 PM EST
€2.48
€0.00(0.00%)
Day’s Range― - ―
52-Week Range€0.35 - €2.64
Previous CloseN/A
Volume0.00
Average Volume (3M)124.00
Market Cap
€109.27M
Enterprise Value€152.96
Total Cash (Recent Filing)€995.98K
Total Debt (Recent Filing)€407.02K
Price to Earnings (P/E)―
Beta0.77
Next Earnings
Nov 13, 2026EPS Estimate
-0.11Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.54
Shares Outstanding63,726,616
10 Day Avg. Volume0
30 Day Avg. Volume124
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)1.73
Price to Sales (P/S)0.00
P/FCF Ratio-1.31
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€8.55Price Target Upside244.92% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.49
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Development PathwayAn investigational new drug submission enabling a planned Phase 2 trial of the anti‑VISTA antibody with a menin inhibitor establishes a clear clinical pathway in relapsed or refractory acute myeloid leukemia and could unlock value if interim data show benefit.
IFx-2.0 Commercial UpsideFDA Orphan Drug Designation for IFx-2.0 in cutaneous melanoma, combined with prior responses in anti‑PD1–refractory patients and analyst valuations that exclude IFx-2.0 revenue, creates potential upside if trials confirm benefit and expand use with Keytruda.
Listing ComplianceRegaining NASDAQ compliance after a rebound driven by renewed interest in the company's AML program reduces delisting risk and restores market visibility, which can support investor confidence.
Bears Say
Clinical And Competitive RiskNegative clinical results, development delays, competition from other checkpoint inhibitors, and the risk of dilutive financing could materially harm shareholder value if key trials fail or commercial uptake is limited.
Operational And Financing RiskSignificant operational setbacks and ongoing financing needs have driven steep share weakness, highlighting execution and funding risks that could pressure the stock through dilution or capital constraints.
Regulatory UncertaintyAn orphan drug designation that does not match the Phase 3 trial's indication introduces uncertainty about how the designation will affect the development plan and potential exclusivity benefits.
TuHURA Biosciences News
PL3 FAQ
What was TuHURA Biosciences’s price range in the past 12 months?
TuHURA Biosciences lowest stock price was €0.35 and its highest was €2.64 in the past 12 months.
What is TuHURA Biosciences’s market cap?
TuHURA Biosciences’s market cap is €109.27M.
When is TuHURA Biosciences’s upcoming earnings report date?
TuHURA Biosciences’s upcoming earnings report date is Nov 13, 2026 which is in 79 days.
How were TuHURA Biosciences’s earnings last quarter?
TuHURA Biosciences released its earnings results on Aug 14, 2026. The company reported -€0.12 earnings per share for the quarter, beating the consensus estimate of -€0.131 by €0.011.
Is TuHURA Biosciences overvalued?
According to Wall Street analysts TuHURA Biosciences’s price is currently Undervalued.
Does TuHURA Biosciences pay dividends?
TuHURA Biosciences does not currently pay dividends.
What is TuHURA Biosciences’s EPS estimate?
TuHURA Biosciences’s EPS estimate is -0.11.
How many shares outstanding does TuHURA Biosciences have?
TuHURA Biosciences has 63,726,616 shares outstanding.
What happened to TuHURA Biosciences’s price movement after its last earnings report?
TuHURA Biosciences reported an EPS of -€0.12 in its last earnings report, beating expectations of -€0.131. Following the earnings report the stock price went down -1.508%.
Which hedge fund is a major shareholder of TuHURA Biosciences?
Currently, no hedge funds are holding shares in DE:PL3
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
TuHURA Biosciences Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€8.55 (244.92% Upside)
€8.55 (244.92% Upside)
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-82.52%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-8.30%
Trailing 12-Months
Company Description
TuHURA Biosciences
TuHURA Biosciences, Inc. is an immuno-oncology firm that has reached the critical Phase 3 registration stage of clinical development. The company is dedicated to pioneering innovative technologies designed to effectively combat the mechanisms by which cancers develop resistance to existing immunotherapy treatments. Its operations are based in Tampa, Florida.
PL3 Stock 12 Month Forecast
Average Price Target
€8.55
▲(244.92% Upside)
Technical Analysis
Agenus
―
Inovio Pharmaceuticals
―
Skye Bioscience
―
Biomea Fusion
―
Cognition Therapeutics
―